Company: HUM
Filing Date: 2025-08-29
Form Type: 8-K
Source: 0000049071-25-000044
Chunk: 0

Company: HUMANA INC
Filing Date: 2025-08-29
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01. Regulation FD Disclosure.

Members of Humana Inc.’s (the “ Company”) senior management team are scheduled to meet with investors and analysts at various meetings between September 1, 2025 and September 30, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $13.77 in diluted earnings per common share (“ EPS”) or approximately $17.00 in adjusted earnings per common share (“ Adjusted EPS”), in each case for the year ending December 31, 2025 (“ FY 2025”). This guidance is consistent with the guidance issued in the Company’s press release dated July 30, 2025.

As indicated on the Company’s second quarter 2025 earnings call on July 30, 2025, the Company will not be commenting on 2026 Medicare Advantage (MA) Star Ratings (Bonus Year 2027) until the Centers for Medicare and Medicaid Services (CMS) releases final 2026 MA Star Ratings data in October.

The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles (“ GAAP”). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company’s core operating performance over time. Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company’s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:

  Diluted earnings per common share                                                                                     FY 2025 Guidance  
  GAAP                                                                                                                  Approximately     
  Amortization of identifiable intangibles                                                                              0.49              
  Put/call valuation adjustments associated with the Company's non-consolidating minority interest investments (a)      3.01              
  Value creation initiatives (a)                                                                                        0.44              
  Impairment charges (a)                                                                                                0.26              
  Cumulative net tax impact                                                                                             (0.97)            
  Adjusted (non-GAAP) – FY 2025 projected (a)                                                                           approximately     

(a) FY 2025 GAAP EPS guidance and FY 2025 Adjusted (non-GAAP) EPS guidance exclude the impact of future value changes to items